vascular endothelial growth factor news

Merck to buy rights to Chinese cancer drug

Merck to buy rights to Chinese cancer drug for up to $3.3B

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a cancer candidate known as LM-299 from the Chinese biotech in a deal worth up to $3.

MM&M · 16h

Merck strikes $3.3B licensing deal for Chinese cancer drug

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Reuters on MSN · 23h

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,

Pharmaceutical Technology2h

MSD secures worldwide license for LaNova’s LM-299

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

Medscape2d

Researchers Identify Why Some Don’t Respond to Anti-VEGF Drugs for AMD

in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his ...

GlobalData on MSN1d

BioNTech signs agreement to acquire Biotheus

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

The Manhattan Mercury10d

Why Treatments Can Fail Folks With 'Wet' Macular Degeneration -- and What Might Really Work

To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...

23h

Merck in Cancer Licensing Pact With LaNova Medicines

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

New Atlas6d

RNA therapy an effective alternative to lifelong, painful eye injections

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Finance News Network23h

Eye on the prize: $15.9m boost for Opthea's vision impairment therapy

Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results